By first restoring and then maintaining adequate peripheral blood levels of CD4+ and CD8+ T lymphocytes this would enable the immune system of an SCC-treated COVID-19 patient to respond appropriately to resolve SARS-CoV-2 infection. This evidence concerns the gene CD8A and COVID-19.